HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on UroGen Pharma (NASDAQ:URGN) with a maintained price target of $54.
May 06, 2024 | 10:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UroGen Pharma receives a reiterated Buy rating and a maintained $54 price target from HC Wainwright & Co.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices. The reiteration of a Buy rating and a high price target suggests a strong vote of confidence in UroGen Pharma's potential, likely leading to positive short-term price movement.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100